ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$0.73 USD
-0.04 (-4.58%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.70 -0.03 (-4.10%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IPA 0.73 -0.04(-4.58%)
Will IPA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 7th
New Strong Buy Stocks for February 5th
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
Other News for IPA
Buy Rating Affirmed: ImmunoPrecise’s Strong Financials and AI Advancements Signal Growth Potential
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2024 Earnings Call Transcript
ImmunoPrecise reports Q4 results
ImmunoPrecise Antibodies reports Q4 revenue C$6.46M vs. C$5.62M last year